Kineret® (anakinra) receives a positive opinion from CHMP for the treatment of Still’s disease

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for anakinra for the treatment of Still’s disease. The opinion is now referred to the European Commission for a decision. Still’s disease is a rare systemic multi-organ disorder of auto-inflammatory nature that affects both children and adults. It is often associated with fever, rash and joint inflammation. Still’s disease is also referred to as systemic juvenile idiopathic